Nektar Therapeutics (NASDAQ:NKTR – Get Free Report) had its target price lifted by analysts at B. Riley from $85.00 to $105.00 in a research note issued on Tuesday,Benzinga reports. According to MarketBeat, Nektar Therapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $91.67. Get Nektar Therapeutics alerts:Check Out Our Latest Analysis on Nektar TherapeuticsNektar Therapeutics Price PerformanceNKTR stock traded down $0.35 during midday trading on Tuesday, reaching $58.54. Nektar Therapeutics (NASDAQ:NKTR – Get Free Report) last issued its quarterly earnings data on Thursday, August 7th. Read MoreReceive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.